R&D News | pharmaphorum

News

Merck's Keytruda flunks another prostate cancer test

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.

News

Pliant seeks $250m offering on lung fibrosis data

Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised

News

Sanofi, CytoReason expand AI deal into IBD

Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the fiel

News

Morphic loses second partner as J&J exits integrin alliance

Morphic Therapeutic has lost Johnson & Johnson's Janssen Pharma as a partner, following the termination of an alliance to develop drugs targeting integrins first agreed in 2019.

News

BeiGene's Brukinsa FDA approved for CLL/SLL

Beijing-based pharma, BeiGene’s

News

Aldo Faisal and Tracking ethomic biomarkers.
Bodily movement sensors combined with new AI tool allow researchers to track movements and predict disease progression in movement disorders.

Aldo is pictured with Ms Luchen Li, Department of Computing who is wearing the sensor suit.

Dr Balasundaram Kadirvelu who leads on the project is pictured seated with Luchen in some of the images with the bodysuit.

Movie motion capture tech tested for disease tracking

Motion capture technology used to bring fantasy characters to life in movies like Avatar and The Lord of the Rings is being used alongside artificial intelligence (AI) to track diseases tha

Merck's Keytruda flunks another prostate cancer test

Pliant seeks $250m offering on lung fibrosis data

Sanofi, CytoReason expand AI deal into IBD

Morphic loses second partner as J&J exits integrin alliance

BeiGene's Brukinsa FDA approved for CLL/SLL

Movie motion capture tech tested for disease tracking

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks